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Background: Inflammation has been linked with development of some cancers. We investigated systemic inflammation in relation
to colorectal cancer incidence and subsequent survival using common serum inflammatory markers
Design: A cohort of men and women aged 20 years and older in greater Stockholm area with serum C-reactive protein (CRP) and
albumin measured between 1986 and 1999 were included (n¼ 325 599). A subset of these had baseline measurements of
haptoglobin and leukocytes. Multivariable Cox regression was performed to assess risk of colorectal cancer by levels of
inflammatory markers, adjusting for potential confounders. Analyses were stratified by circulating glucose, total cholesterol and
triglycerides. Overall and CRC-specific death following diagnosis were assessed as secondary outcomes.
Results: A total of 4764 individuals were diagnosed with colorectal cancer. A positive association between haptoglobin and
colorectal cancer incidence was found (hazard ratio (HR): 1.17; 95% CI: 1.06–1.28). A positive association was also observed with
leukocytes (HR: 1.21; 95% CI: 1.03–1.42). No evidence of association was noted between CRP and colorectal cancer risk. Higher
risks of all-cause death were seen with haptoglobin and leukocytes levels. Higher haptoglobin levels were linked with an increased
risk of colorectal cancer death (HR: 1.19; 95% CI: 1.01–1.41).
Conclusions: Prediagnostic systemic inflammation may impact colorectal cancer incidence and survival; therefore, prompting
investigations linking inflammatory pathways preceding colorectal cancer with disease severity and progression.
Evidence suggesting a role for inflammation in colorectal
carcinogenesis is growing (Hanahan and Weinberg, 2011). For
instance, inflammatory bowel disease, reflecting local inflammation
of the colon, has been associated with an increased risk of
colorectal cancer (Jess et al, 2012). The role of systemic
inflammation in colon carcinogenesis, however, remains unclear.
Chronic inflammation may initiate and promote cancer through
the generation of proinflammatory cytokines and reactive oxygen
species, such as interleukin-6 (IL-6), which activates transcription
factors that can promote the growth of a tumour (Meira et al,
2008). Increases in white blood cells can also lead to a ‘respiratory
burst’ due to an increased uptake of oxygen, resulting in more
reactive oxygen species at the site of damage and DNA damage
consequently (Reuter et al, 2010).
In the context of colorectal cancer, over 19 observational studies
have investigated a link with prediagnostic levels of inflammatory
markers over the past decade (Supplementary Table S1). Most of
these studies have used C-reactive protein (CRP). Findings varied,
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with nine studies having reported a positive association between
CRP and colorectal cancer risk. A meta-analysis in 2013 found no
statistical significance (hazard ratio (HR) 1.055; 95 CI: 0.925–
1.184), but concluded there could be a possible link between
elevated CRP levels and colorectal cancer (Guo et al, 2013).
Therefore, the link between markers of chronic inflammation and
risk of colorectal cancer is still unclear.
We investigated the link between inflammation and colorectal
cancer risk in a cohort of the Apolipoprotein Mortality Risk Study
(AMORIS) Study (n¼ 325 599). In addition to commonly studied
CRP, we also assessed albumin, haptoglobin and white blood cells
as markers of inflammation in relation to risk of colorectal cancer.
C-reactive protein, an acute phase reactant, is elevated in response
to inflammation following a rise in proinflammatory interleukin-6
(IL-6) and is the most widely used marker to assess inflammation
in clinic (Skinner et al, 2010). Similar to CRP, haptoglobin levels
also rise in the presence of increased IL-6 levels (Rodriguez-
Hernandez et al, 2013). On the other hand, albumin levels drop in
response to inflammation; hence, albumin is regarded as a negative
acute phase reactant (Fox et al, 2013). Second, we studied
prediagnostic levels of these inflammatory markers in relation to
survival among colorectal cancer patients (n¼ 4764). We also
considered metabolic disorders by assessing serum markers of
glucose and lipid metabolism.
MATERIALS AND METHODS
Study population. The AMORIS Study has been described in
further detail elsewhere (Holme et al, 2010). Briefly, this cohort
consists of men and women from the greater Stockholm area
in Sweden who underwent clinical laboratory testing at the
Central Automation Laboratory (CALAB) in Stockholm, Sweden,
with follow-up information collected from Swedish national
registries. In CALAB, over 500 blood biomarkers were collected
between 1986 and 1996. All the individuals at the time were either
healthy individuals referred for clinical laboratory testing as part of
a general health check-up or were outpatients. None of the
individuals were in-patients at the time their blood samples were
taken. Apart from the information on blood testing, no clinical
data was included in the CALAB database. With a ten-digit
personal identification number, the CALAB database was linked to
several Swedish national registries such as the National Cancer
Register, the Hospital Discharge Register, the Cause of Death
Register, the consecutive Swedish Censuses during 1970–1990 and
the National Register of Emigration. These databases provided data
on socioeconomic status, vital status, cancer diagnosis, comorbidity
and emigration. All aspects of the AMORIS Study complied with
the Declaration of Helsinki and the ethics review board of
Karolinska Institute approved the AMORIS Study.
For this study, all individuals aged 20 years and older with
baseline measurements of CRP and albumin (n¼ 325 599) were
included, among which 218 158 also had baseline haptoglobin
levels measured, 96 821 had leukocytes measurements and 57 340
participants had body mass index (BMI) measurements. None of
the participants had a history of cancer at baseline. Participants
with measurements of serum inflammatory markers taken within 2
years before the end of follow-up were excluded to reduce the
possibility of reverse causation.
Outcome assessment. The main outcome of interest was
diagnosis of colorectal cancer as obtained from the Swedish
Cancer Register using the International Code of Diseases, version 7
(ICD-7 code: 153-154). As a secondary outcome, we investigated
mortality from colorectal cancer and from all causes for which we
obtained information from the Cause of Death Register. The
follow-up time for the primary outcome was defined as the time
from baseline measurement entry until time of colorectal cancer
diagnosis, death, emigration out of Sweden or the closing date of
the study (31 December 2011), whichever came first. Those who
were diagnosed with CRC in this study were then followed to
assess death from all causes and from CRC as the second outcome.
For the mortality outcomes, follow-up time was defined from the
diagnosis of colorectal cancer to either death, end of follow-up or
date of emigration out of Sweden, whichever came first.
Serum inflammatory markers. Serum CRP and haptoglobin
levels were measured with an immunoturbidimetric assay (reagents
from Orion Diagnostics, Espoo, Finland). These were analysed
using fully automated multichannel analysers. For CRP, an Auto
Chemist-PRISMA was used from 1985 to 1992 and from 1993 to
1996 a DAX96 from Technicon Instruments (Bayer Diagnostics,
New York, NY, USA) was used. Hitachi-analysers (Mannheim,
Germany) were used to analyse haptoglobin (Holme et al, 2010).
At the time of laboratory examination (1985–1996), high-
sensitivity CRP (hs-CRP) was not available and CRP concentra-
tions below the level of 10mg l 1 could not be discriminated.
However, the cutoff point of 10mg l 1 is widely accepted as the
upper limit of the health-associated reference range (Wilkins et al,
1998). Albumin was measured with a bromcresol green method.
Leukocyte count was measured with routinely used haematology
analysers from STKS Haematology System (Beckman Coulter Inc.,
Fullerton, CA, USA). Total imprecision calculated by the coeffi-
cient of variation was 12% for CRP, 5.6% for haptoglobin, o1.8%
for albumin and for o2.7% for leukocytes (Wulaningsih et al,
2015). Central Automation Laboratory performed all laboratory
procedure and complied with the WHO international federation of
clinical chemistry protocols standard programmes (Jungner et al,
1998).
Covariates. In addition to the inflammatory markers of interest,
information on serum levels of glucose, triglycerides (TGs) and
total cholesterol (TC) levels were collected due to research
indicating metabolic syndrome, specifically its components as
potential confounders (Esposito et al, 2013). Glucose was measured
with a glucose oxidase/peroxidase method (Holme et al, 2010).
Total cholesterol and TGs were measured enzymatically with
standardised procedures. Body mass index was calculated from
weight (kg) and height (m) measured at CALAB. Information on
education and social economic status (SES) was obtained from the
national censuses. History of ulcerative colitis (UC) was obtained
from the National Patient Register. Also from the National Patient
Register, comorbidities were assessed as the Charlson comorbidity
index (CCI), which consists of 17 groups of diseases with a specific
weight assigned to each disease category (D’Hoore et al, 1996).
These weights were then summed to obtain an overall score,
resulting in four comorbidity levels (0, 1, 2 and 3þ ), indicating no
comorbidity to severe comorbidity. Period of diagnosis was
categorised (before and after 2008) to account for colorectal
cancer screening introduced in Sweden from 2008 (Blom et al,
2014). Interval time was defined as time between blood test and the
time of diagnosis of colorectal cancer. Information on tumour
stage was available for 2474 out of 4764 colorectal cancer cases
from the Swedish Cancer Registry.
Statistical analysis. First, risk of colorectal cancer associated with
continuous log-transformed values of systemic inflammatory
markers (C-reactive protein, albumin, haptoglobin and leukocytes)
were analysed using unadjusted Cox proportional hazard regres-
sion models. For CRP, all logarithmic analysis was carried out with
participants who had CRP values 410mg l 1. Proportionality of
the hazard was checked with Kaplan–Meier curves and the
assumption of proportionality was not violated. Additionally,
inflammatory markers were assessed as categories, with CRP
divided into five categories (o10, 10–15, 15–25, 25–50 and
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450mg l 1) and other markers assessed as quartiles. A linear test
for trend was conducted by using categories as an ordinal scale. We
subsequently conducted multivariable analyses with models
adjusted for age (continuous), sex, educational level, SES, CCI
and history of UC. Additional adjustments were carried out with
continuous glucose, TG and TC levels to take into account the
impact of obesity-related metabolic disorders on inflammation and
CRC risk. In the subgroup with BMI, the same Cox regression
analysis with similar adjustments was carried out to observe
whether associations were similar between the participants who
had BMI measurements and the total study population. We then
conducted a similar analysis with an additional adjustment for
BMI in this subgroup. Finally, stratification analyses were performed
by dichotomised levels of glucose, TG and TC based on the
NCEP guidelines (NCEP, 2001): 7, 1.71 and 6.50mmol l 1,
respectively. Some participants may have had a transient rise in
CRP due to acute infections; therefore, a sensitivity analysis was
conducted by repeating analyses while excluding all participants with
CRP 420mg l 1.
For the second outcome, the associations with continuous
logarithmic and categories of systemic inflammatory markers
(CRP, albumin, haptoglobin and leukocytes) were analysed using
crude and multivariable Cox proportional hazard regression
models. Two outcomes were analysed: all-cause death and colo-
rectal cancer-specific death. The multivariable models were
adjusted for age of diagnosis, interval time, period diagnosis and
sex. A second model was carried out with additional adjustment for
TNM staging.
All analyses were carried out using Statistical Analysis Systems
(SAS) release 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
During a mean follow-up time of 18 years, 4764 out of 325 599
participants (1.46%) developed invasive colorectal cancer. Table 1
shows participant characteristics by colorectal cancer diagnosis.
Over 90% of participants were gainfully employed.
Higher levels of haptoglobin and leukocytes levels were
associated with increased colorectal cancer risk in the crude model
(Table 2). In the second model adjusted for age, sex, education,
SES, CCI and UC, these trends weakened slightly, with HRs of 1.19
(95% CI: 1.09–1.31) and 1.25 (95% CI: 1.07–1.46) for highest vs
lowest quartile in haptoglobin and leukocytes, respectively. When
additionally adjusted for glucose, TG and TC levels, there was no
large difference observed; for instance, the HR for the fourth
quartile of haptoglobin was 1.17 (95% CI: 1.06–1.28) and that of
leukocytes was 1.21 (1.03–1.42), compared with the first quartiles
of the markers. A strong inverse trend was observed between
albumin and colorectal cancer risk in the crude model. However,
upon adjustments (model 2) the trend became weaker
(Ptrend¼ 0.06). When additionally adjusted for metabolic markers,
a borderline negative association was observed with an HR of 0.91
(95% CI: 0.83–1.00) for the fourth compared with the first quartile
(Ptrend¼ 0.02). An additional test was carried out in the subgroup
with information on BMI (Supplementary Table S2). In this model,
similar underlying trends were observed. When adjusting the
analysis for BMI in this subgroup, no marked changes were
observed in the risk estimates and confidence intervals.
Supplementary Table 3 shows associations between continuous
log and categories of systemic inflammatory markers and color-
ectal cancer incidence, stratified by metabolic markers. No
substantial interaction between levels of inflammatory markers
and glucose, TG or TC was indicated (Pinteraction40.05).
A sensitivity analysis excluding those with CRP420 to exclude
acute inflammation showed similar findings (no results shown).
Table 3 shows the characteristics of participants who were
diagnosed with colorectal cancer by survival status. Out of the 4764
persons diagnosed with CRC, 2257 died during follow-up, of which
1467 died specifically of CRC. The mean follow-up time from
diagnosis to death was 4.64 years.
Table 4 displays associations between prediagnostic inflamma-
tory markers and all-cause death. Upon adjustment for age of
diagnosis, sex, interval time and period of diagnosis, positive
associations were observed for haptoglobin (HR: 1.16; 95% CI:
1.02–1.32 for the fourth quartile compared with the first) and
leukocytes (HR: 1.53; 95% CI: 1.23–1.90 for the fourth quartile
compared with the first) in relation to risk of dying from all causes.
No associations were observed for albumin in the multivariable
models. Additional adjustments for TNM staging showed similar
trends (Table 4).
When assessing colorectal cancer-specific death in the crude
models, significant trends for albumin, haptoglobin and leukocytes
were observed (Table 5). In the fully adjusted models, there was
only a significant association between haptoglobin and colorectal
cancer death (HR: 1.19; 95% CI: 1.01–1.41) for the highest
compared with the lowest quartile.
DISCUSSION
This is the largest study to date assessing the association between
colorectal cancer risk and widely available clinical markers of
inflammation in addition to CRP. To our knowledge, this is the
first study to assess the relationship between haptoglobin, albumin
and leukocytes in relation to CRC incidence and survival. Despite
the lack of an association with CRP, we found an increased risk of
Table 1. Characteristics of study participants
Colorectal
cancer,
N¼4764
No
colorectal,
cancer
N¼320835
All
participants,
N¼325599
Age (years)
Mean (s.d.) 56.21 (11.00) 45.66 (13.92) 45.81 (13.94)
SES
White collar 2465 (51.74) 151 315 (47.16) 153 780 (47.23)
Blue collar 1908 (40.05) 137 574 (42.88) 139 482 (42.84)
Not gainfully
employed or missing
391 (8.21) 31 946 (9.96) 32 337 (9.93)
Education category
Low 1579 (33.14) 78 522 (24.47) 80 101 (24.60)
Middle 1880 (39.46) 139 964 (43.62) 14 1844 (43.56)
High 1155 (24.24) 92 187 (28.73) 93 342 (28.67)
Missing 150 (3.15) 10 162 (3.17) 10 312 (3.17)
Follow-up time (years)
Mean (s.d.) 12.88 (5.50) 18.64 (4.51) 18.56 (4.58)
Median 13.00 19.04 18.97
Min 2.01 2.00 2.00
Max 24.58 24.83 22.19
Comorbidity index
0 4385 (92.04) 301 930 (94.11) 306 315 (94.08)
1 282 (5.92) 13 567 (4.23) 13 849 (4.25)
2 63 (1.32) 3226 (1.01) 3289 (1.01)
3þ 34 (0.71) 2112 (0.66) 2146 (0.66)
Ulcerative colitis 7 (0.15) 292 (0.09) 299 (0.09)
CRP (mg l 1)
Mean (s.d.)a 18.92 (39.60) 19.43 (38.35) 19.42 (38.37)
Albumin (g l1)
Mean (s.d.) 42.48 (2.69) 43.30 (2.87) 43.29 (2.87)
Haptoglobin (g l 1)
Mean (s.d.) 1.10 (0.31) 1.04 (0.3) 1.05 (0.30)
Leukocytes (109/l)
Mean (s.d.) 6.68 (1.95) 6.61 (2.15) 6.61 (2.15)
Abbreviations: CRP¼C-reactive protein; SES¼ social economic status.
aCRP410mg l 1.
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colorectal cancer with higher levels of haptoglobin and leukocytes
and a borderline inverse association with albumin. For colorectal
cancer-specific death, the only positive association observed was
with haptoglobin.
Biological studies linking inflammation to colorectal cancer and
cancer development in general have suggested a role of cancer
initiation and promotion by reactive oxygen species, which is
produced during inflammation (Wiseman and Halliwell, 1996;
Waris and Ahsan, 2006). Proinflammatory cytokine IL-6 released
during inflammation may trigger the activation of signal
transducer and activator of transcription 3 (STAT3) and nuclear
factor-kB (NF-kB) pathways (Hodge et al, 2005; Wang et al, 2009;
Yu et al, 2009). Activation of these pathways has been widely
implicated in colitis-associated colorectal cancer (Wang et al,
2009). Additionally, increased levels of circulating proinflamma-
tory cytokines are also observed in chronic systemic inflammation
(Gabay, 2006). These signalling pathways may induce upregulation
of genes involved in cell proliferation and survival, and increased
localisation of b-catenin, which contributes to colorectal cancer
carcinogenesis (Bollrath et al, 2009). In the context of cancer
progression, current experimental research suggests that the
activation of STAT3 from cytokine IL-6 suppresses the MIR34A
gene (Rose-John, 2012; Rokavec et al, 2014), resulting in the
activation of epithelial-to-mesenchymal transition and subsequent
metastasis of the cancer (Hahn et al, 2013; Siemens et al, 2013;
Rokavec et al, 2014).
This study showed significant positive associations between
prediagnostic markers haptoglobin and leukocytes with colorectal
cancer risk. In recent years, there has been increasing evidence
linking serum haptoglobin and other cancers; for instance, breast
cancer (Wulaningsih et al, 2015). Experimental studies have
shown that haptoglobin contributes to increased oxidative stress
and low-grade chronic inflammation (Ye et al, 2003; A´lvarez-
Blasco et al, 2009). Serum haptoglobin levels rise for longer periods
following an external insult compared with other inflammatory
markers such as CRP, which fluctuates and drops rapidly after a
proinflammatory stimulus (Gabay and Kushner, 1999). This
variation in bioavailability of the markers may explain the
difference in results observed between the two markers. Further-
more, this may indicate that haptoglobin, in addition to its role as
an inflammatory marker, could be directly involved in CRC
carcinogenesis. Further studies are necessary to contrast the role of
haptoglobin with other markers such as CRP as markers of chronic
inflammation in the context of cancer. Higher quartiles of
leukocytes showed a positive association with risk of colorectal
cancer. This positive association agrees with findings indicating the
role of IL-6, which is released by specific leukocytes, in CRC
carcinogenesis (Patel et al, 2014).
In keeping with the majority of current studies, our finding
found no evidence of association between elevated CRP and CRC.
As already mentioned, of the 19 prospective studies that have been
published to date, only nine found that CRP is associated with an
increased risk of colorectal cancer (Supplementary Table S1).
However, the largest number of colorectal cancer cases among these
prior studies was 729 (Lee et al, 2011). In addition to sample size,
adjustments for potential confounders such as BMI and other
lifestyle factors may explain the differences in estimates. Although
our analysis in the subgroup with BMI information was hampered by
low statistical power, we observed similar results before and after
adjustment for BMI or markers of glucose and lipid metabolisms.
Table 2. Associations between inflammatory markers and risk of CRC
Marker n CRC/n total Hazard ratio (95% CI)a Hazard ratio (95% CI)b Hazard ratio (95%)c
CRP (mg l1)
Continuous logd 295/17 852 0.91 (0.77–1.07) 0.85 (0.72–1.01) 0.87 (0.73–1.04)
o10 3930/27 9599 1 (reference) 1 (reference) 1 (reference)
10–15 635/33 556 1.12 (1.03–1.22) 1.02 (0.94–1.11) 1.03 (0.90–1.34)
15–25 104/6053 1.26 (1.04–1.53) 1.11 (0.92–1.35) 1.10 (0.90–1.34)
25–50 57/3953 1.05 (0.81–1.36) 0.88 (0.68–1.14) 0.93 (0.72–1.21)
450 38/2438 1.14 (0.83–1.57) 0.89(0.65–1.23) 0.88 (0.63–1.23)
Ptrend o0.01 0.8 1
Albumin (g l1)
Continuous log 4764/32 5599 0.02 (0.01–0.03) 0.69 (0.43–1.09) 0.58 (0.36–0.95)
o41 1065/51 719 1 (reference) 1 (reference) 1 (reference)
41–43 1365/74 713 0.85(0.79–0.92) 1.00 (0.92–1.08) 1.00 (0.92–1.08)
43–45 1290/90 321 0.67 (0.67–0.62) 0.95 (0.87–1.03) 0.94 (0.86–1.02)
445 1044/108 846 0.47 (0.47–0.43) 0.93 (0.85–1.02) 0.91 (0.83–1.00)
Ptrend o0.0001 0.06 0.02
Haptoglobin (g l1)
Continuous log 3645/218 158 2.01 (1.86–2.36) 1.28 (1.14–1.44) 1.24 (1.10–1.40)
o0.90 704/53 597 1 (reference) 1 (reference) 1 (reference)
0.90–1.00 470/30 725 1.19 (1.06–1.34) 1.083 (0.96–1.22) 1.09 (0.97–1.22)
1.00–1.20 1090/66 060 1.31 (1.19–1.44) 1.07 (0.97–1.18) 1.06 (0.96–1.17)
41.20 1381/67 776 1.70 (1.56–1.86) 1.19 (1.09–1.31) 1.17 (1.06–1.28)
Ptrend o0.0001 0.0002 0.002
Leukocytes (109/l)
Continuous log 1392/96 821 1.322 (1.10–1.56) 1.37 (1.13–1.65) 1.30 (1.07–1.58)
o5.20 284/22 495 1 (reference) 1 (reference) 1 (reference)
5.2–6.3 355/25 147 1.15 (0.98–1.34) 1.10 (0.94–1.28) 1.08 (0.92–1.27)
6.3–7.6 386/24 223 1.32 (1.13–1.54) 1.24 (1.06–1.45) 1.22 (1.04–1.43)
47.6 367/24 956 1.23 (1.07–1.45) 1.25 (1.07–1.46) 1.21 (1.03–1.42)
Ptrend 0.002 0.002 0.008
Abbreviations: CRC¼ colorectal cancer; CRP¼C-reactive protein; UC=ulcerative colitis.
aCrude model.
bAdjusted for age, sex, education and socioeconomic status, Charlson comorbidity index and UC.
cAdjusted for age, sex, education and socioeconomic status, Charlson comorbidity index and UC, glucose, total cholesterol and triglycerides.
dCRP410mg l 1.
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Table 3. Characteristics of survival study participants
All-cause death (n¼2257) CRC death (n¼1467) Alive (n¼2507) All CRC patients (n¼4764)
Age at diagnosis 71.16 (10.72) 69.32 (10.78) 67.04 (10.06) 68.99 (10.58)
Sex
Male 1329 (48.47) 838 (30.56) 1413 (51.53) 2742 (57.66)
Female 928 (45.90) 629 (13.20) 1094 (54.10) 2022 (42.44)
Interval between marker
measurements and diagnosis
(years)
10.91 (5.17) 11.21 (5.23) 14.46 (5.2) 12.78 (5.50)
Follow-up since diagnosis (years) 2.98 (3.35) 2.00 (2.12) 6.13 (4.87) 4.64 (4.50)
Period diagnosis
o2008 1959 (86.80) 1246 (84.94) 1432 (57.12) 3391 (77.18)
42008 298(13.20) 221(15.06) 1075(42.88) 1373(28.82)
TNM staging
Tumour
pT2 118 (5.23) 54 (3.68) 588 (23.45) 706 (14.82)
4T2 656 (29.07) 470 (32.04) 1112 (44.36) 1768 (37.11)
Tx/unknown 1483 (65.71) 943 (64.28) 807 (32.19) 2290 (48.07)
Nodes
No 292 (12.94) 138 (9.41) 1051 (41.92) 1343 (28.19)
Yes 443 (19.63) 362 (24.68) 577 (23.02) 1020 (21.41)
Nx/Missing 1522 (67.43) 967 (65.92) 879 (35.06) 2401 (50.40)
Metastasis
No 449 (19.89) 237 (16.16) 1204 (48.03) 1653 (34.70)
Yes 429 (19.01) 391 (26.65) 110 (4.39) 539 (11.31)
Mx/Unknown 1379 (61.10) 839 (57.19) 1193 (47.59) 2572 (53.99)
Markers
CRP (mg l 1)
Mean (s.d.)a 18.92 (39.60) 18.35 (31.35) 19.43 (38.35) 18.92 (39.60)
Albumin (g l 1)
Mean (s.d.) 42.14 (2.72) 42.27 (2.71) 42.78 (2.63) 42.48 (2.96)
Haptoglobin (g l 1)
Mean (s.d.) 1.13 (0.33) 1.12 (0.32) 1.07 (0.29) 1.10 (0.31)
Leukocytes (109/l)
Mean (s.d.) 6.76 (1.97) 6.74 (2.06) 6.59 (1.93) 6.68 (1.95)
Abbreviations: CRC¼ colorectal cancer; CRP¼C-reactive protein; TNM= tumour node metastasis.
aCRP410mg l.
Table 4. Associations between prediagnostic inflammatory markers and all-cause death
Marker N event/N total Hazard ratios (95% CI)a Hazard ratios (95% CI)b Hazard ratios (95% CI)c
CRP (mg l1)
Continuous logd 149/295 0.96 (0.79–1.18) 0.93 (0.75–1.15) 0.92 (0.74–1.14)
o10 1834/3930 1 (reference) 1 (reference) 1 (reference)
10–15 322/635 1.06 (0.94–1.19) 1.04 (0.92–1.17) 1.02 (0.91–1.15)
15–25 51/104 1.01 (0.77–1.34) 0.86 (0.65–1.14) 0.92 (0.70–1.22)
25–50 29/57 1.17 (0.81–1.69) 1.17 (0.81–1.69) 1.28 (0.89–1.85)
450 21/38 1.11 (0.72–1.70) 1.03 (0.67–1.58) 1.07 (0.70–1.65)
Ptrend 0.26 0.8 0.5
Albumin
Continuous log 2256/4764 0.13 (0.07–0.24) 0.63 (0.32–1.25) 0.57 (0.29–1.14)
o41 615/1065 1 (reference) 1 (reference) 1 (reference)
41–43 626/1365 0.76 (0.68–0.85) 0.82 (0.74–0.92) 0.88 (0.78–0.98)
43–45 601/1290 0.79 (0.71–0.89) 0.97 (0.86–1.08) 1.00 (0.89–1.12)
445 415/1044 0.68 (0.60–0.77) 0.90 (0.79–1.02) 0.88 (0.77–1.00)
Ptrend o0.0001 0.44 0.28
Haptoglobin
Continuous log 1793/3645 1.38 (1.16–1.63) 1.27 (1.07–1.50) 1.28 (1.08–1.51)
o0.90 324/704 1 (reference) 1 (reference) 1 (reference)
0.90–1.00 192/470 0.87 (0.73–1.04) 0.87 (0.72–1.03) 0.91 (0.76–1.08)
1.00–1.20 523/1090 1.04 (0.90–1.19) 1.02 (0.89–1.17) 1.04 (0.91–1.20)
41.20 755/1381 1.22 (1.07–1.39) 1.16 (1.02–1.32) 1.19 (1.05–1.36)
Ptrend 0.0001 0.002 0.001
Leukocytes (109/l)
Continuous log 741/1392 1.42 (1.10–1.85) 1.64 (1.25–2.15) 1.63 (1.26–2.12)
o5.20 136/284 1 (reference) 1 (reference) 1 (reference)
5.2–6.3 194/355 1.30 (1.04–1.62) 1.30 (1.04–1.62) 1.35 (1.08–1.69)
6.3–7.6 201/386 1.23 (0.99–1.53) 1.19 (0.95–1.48) 1.29 (1.04–1.61)
47.6 210/367 1.41 (1.14–1.75) 1.53 (1.23–1.90) 1.55 (1.25–1.93)
Ptrend 0.006 o0.001 o0.001
Abbreviations: CI¼ confidence interval; CRP¼C-reactive protein; TNM= tumour node metastasis.
aCrude model.
bAdjusted for age of diagnosis, interval time, period of diagnosis and sex.
cAdjusted for age of diagnosis, interval time, period of diagnosis and sex and TNM staging.
dCRP410mg l 1.
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For the mortality outcomes, haptoglobin was the only one that
showed a positive association with colorectal cancer death. Our
findings suggest better overall survival with low or normal levels of
haptoglobin and leukocytes before diagnosis, indicating a role of
prediagnostic inflammation in survival after diagnosis. There is
currently limited data on prediagnostic serum inflammatory
markers and CRC survival. In a study by Allin et al (2009), levels
of prediagnostic CRP levels and the risk of death from cancer was
studied. They found elevated baseline CRP to be associated with
early death after a diagnosis of any cancer, particularly in patients
without metastases. However, the study by Allin et al (2009) only
had 191 patients with colorectal cancer, which may explain the
difference with the present study. Associations observed in our
study were stronger for all-cause death than colorectal cancer
death. This may indicate a competing risk situation, in which dying
from other causes, such as cardiovascular disease, may remove
patients from being at risk of dying from colorectal cancer
(Satagopan et al, 2004). Therefore, analysis of cancer-specific death
is necessary in studying the potential role of elevated prediagnostic
inflammation in cancer survival.
Strengths and limitations. The major strength of this study is the
large number of participants and cases of colorectal cancer. To
date, this is by far the largest population-based study assessing
common inflammatory markers and colorectal cancer. The largest
study to date had 1096 cases of colorectal cancer (Aleksandrova
et al, 2010). This study was also the first to assess the relationship
between haptoglobin, albumin and leukocytes in relation to CRC
incidence and survival. All biomarker analyses for this study were
performed at the same laboratory in Stockholm. Moreover, data for
all participants in this study was taken from national registers,
providing complete follow-up for all study participants and
detailed information on participant’s comorbidities, cancer diag-
nosis, deaths and social statuses. The population in the study was
selected by the analysis of fresh blood samples from non-
hospitalised individuals. However, any healthy cohort effect would
not have an effect on the internal validity of the study (Van
Hemelrijck et al, 2011).
One of the main limitations of this study is that hs-CRP was not
available at the time the blood samples were analysed. Therefore, it
was not possible to quantify any CRP value below 10mg l 1. This
may have resulted in the underestimation of the association
between serum CRP and colorectal cancer. However, to the best of
our knowledge, there has been no study to address the difference
between using non-hs-CRP and hs-CRP in the context of cancer
risk. We have also used the cutoff that has been suggested has
medically relevant when using non hs-CRP (Wilkins et al, 1998).
The majority of participants had undetectable CRP levels, which
hampered our analysis using continuous CRP. Therefore, similar to
the previous study, we assessed CRP in categories (Van Hemelrijck
et al, 2011). Participants with measurements of serum inflamma-
tory markers taken within 2 years before colorectal cancer
diagnosis were excluded to reduce the possibility of reverse
causation. However, colorectal cancer usually develops years before
diagnosis. During the earlier years, before screening was common,
this long latency period may have had a greater impact. Therefore,
our analysis was adjusted for period of diagnosis to account for the
differences in early detection and management of colorectal cancer
Table 5. Associations between prediagnostic inflammatory markers and colorectal cancer death
Marker N event/N total Hazard ratios (95% CI)a Hazard ratios (95% CI)b Hazard ratios (95% CI)c
CRP (mg l1)
Continuous logd 86/295 0.96 (0.79–1.18) 0.95 (0.72–1.26) 0.96 (0.73–1.27)
o10 1211/3930 1 (reference) 1 (reference) 1 (reference)
10–15 196/635 1.06 (0.94–1.19) 1.00 (0.86–1.16) 0.99 (0.85–1.16)
15–25 32/104 1.01 (0.77–1.34) 0.90 (0.63–1.27) 1.03 (0.73–1.47)
25–50 17/57 1.17 (0.81–1.69) 1.01 (0.63–1.64) 1.20 (0.75–1.95)
450 11/38 1.11 (0.72–1.70) 0.89 (0.49–1.61) 0.99 (0.54–1.79)
Ptrend 0.25 0.64 0.73
Albumin (g l1)
Continuous log 1466/4764 0.13 (0.07–0.24) 0.52 (0.22–1.22) 0.36 (0.16–0.85)
o41 372/1065 1 (reference) 1 (reference) 1 (reference)
41–43 399/1365 0.76 (0.68–0.85) 0.84 (0.73–0.97) 0.89 (0.77–1.03)
43–45 403/1290 0.79 (0.71–0.89) 0.96 (0.83–1.11) 0.97 (0.83–1.12)
445 293/1044 0.68 (0.60–0.77) 0.89 (0.76–1.05) 0.84 (0.72–0.99)
Ptrend o0.0001 0.45 0.1
Haptoglobin (g l1)
Continuous log 1150/3645 1.38 (1.16–1.63) 1.14 (0.92–1.40) 1.17 (0.95–1.45)
o0.90 201/704 1 (reference) 1 (reference) 1 (reference)
0.90–1.00 134/470 0.87 (0.73–1.04) 0.99 (0.79–1.23) 1.04 (0.84–1.30)
1.00–1.20 356/1090 1.04 (0.90–1.19) 1.13(0.95–1.34) 1.15 (0.97–1.37)
41.20 460/1381 1.22 (1.07–1.39) 1.15 (0.97–1.36) 1.19 (1.01–1.41)
Ptrend 0.0001 0.05 0.03
Leukocytes (109/l)
Continuous log 442/1392 1.42 (1.10–1.85) 1.34 (0.95–1.90) 1.31 (0.94–1.83)
o5.20 88/284 1 (reference) 1 (reference) 1 (reference)
5.2–6.3 118/355 1.30 (1.04–1.62) 1.17 (0.89–1.54) 1.22 (0.93–1.61)
6.3–7.6 110/386 1.23 (0.99–1.53) 0.97 (0.73–1.29) 1.10 (0.83–1.46)
47.6 126/367 1.41 (1.14–1.75) 1.28 (0.97–1.68) 1.28 (0.97–1.68)
Ptrend 0.006 0.21 0.16
Abbreviations: CI¼ confidence interval; CRP¼C-reactive protein; TNM= tumour node metastasis.
aCrude model.
bAdjusted for age of diagnosis, interval time, period of diagnosis and sex.
cAdjusted for age of diagnosis, interval time, period of diagnosis and sex and TNM staging.
dCRP410mg l 1.
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overtime. Since cancer may influence levels of serum inflammatory
markers, residual confounding may still have occurred despite
exclusion of participants with history of any cancer at baseline.
Owing to the rounding of the marker levels to 2 decimal places, the
distribution of the markers was not completely equal between the
quartiles. In this study, we were not able to adjust for exercise,
alcohol intake, fruit and vegetable and/or fibre intake, aspirin and
other NSAID use owing to the lack of information in this study. We
did not have information on Crohn’s disease; however, the history of
UC was included in our analysis to account for inflammatory bowel
disease. The AMORIS population is representative of the general
working population of Stockholm (Walldius et al, 2001). However,
this healthy cohort effect does not influence the internal validity of the
study. The markers assessed in this study were measured at one single
point in time, which may be prone to a non-differential measurement
error and this may have resulted in the underestimation of the
associations observed in this study. Finally, detailed histopathological
information of the tumour was not available and it may benefit future
studies to further explore whether prediagnostic inflammation
corresponds to any specific or molecular subtypes of colorectal cancer.
CONCLUSION
We found that altered levels of prediagnostic inflammatory
markers may be associated with an increased risk of colorectal
cancer and worse cancer-specific survival after diagnosis. These
findings support the importance of systemic inflammation
preceding cancer diagnosis in affecting subsequent risk of
incidence and survival. Therefore, this denotes the importance to
study the roots of systemic inflammation and pathways specific to
the development and progression of colorectal cancer.
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